Nathan Demars

405 total citations
13 papers, 37 citations indexed

About

Nathan Demars is a scholar working on Oncology, Biotechnology and Genetics. According to data from OpenAlex, Nathan Demars has authored 13 papers receiving a total of 37 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Biotechnology and 5 papers in Genetics. Recurrent topics in Nathan Demars's work include CAR-T cell therapy research (8 papers), Cancer Research and Treatments (7 papers) and Virus-based gene therapy research (5 papers). Nathan Demars is often cited by papers focused on CAR-T cell therapy research (8 papers), Cancer Research and Treatments (7 papers) and Virus-based gene therapy research (5 papers). Nathan Demars collaborates with scholars based in United States, France and Germany. Nathan Demars's co-authors include Jill Buck, E. Antonio Chiocca, Yunxia Wang, John Barrett, Rimas V. Lukas, Laurence J.N. Cooper, Ganesh Rao, Maria Pia Morelli, Christina Amidei and François Lebel and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Neuro-Oncology.

In The Last Decade

Nathan Demars

12 papers receiving 34 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathan Demars United States 4 27 14 11 11 9 13 37
Virginia Laspidea Spain 3 32 1.2× 13 0.9× 21 1.9× 17 1.5× 22 2.4× 10 53
Carmel Rice United Kingdom 4 23 0.9× 16 1.1× 14 1.3× 30 2.7× 13 1.4× 6 74
Jaap A. van Doesum Netherlands 6 46 1.7× 5 0.4× 10 0.9× 10 0.9× 7 0.8× 11 63
Cody Coblentz United States 2 13 0.5× 14 1.0× 22 2.0× 12 1.1× 9 1.0× 5 52
Valentina Bonuomo Italy 4 23 0.9× 8 0.6× 10 0.9× 10 0.9× 3 0.3× 10 50
Jérôme Paillassa France 6 38 1.4× 35 2.5× 18 1.6× 23 2.1× 10 1.1× 20 78
Nelli Frank Austria 4 25 0.9× 17 1.2× 30 2.7× 27 2.5× 6 0.7× 6 90
Daniel de la Nava Spain 5 39 1.4× 15 1.1× 34 3.1× 19 1.7× 26 2.9× 10 80
Pere Barba Spain 4 59 2.2× 6 0.4× 13 1.2× 11 1.0× 13 1.4× 17 67
Suki Subbiah United States 5 31 1.1× 23 1.6× 10 0.9× 12 1.1× 2 0.2× 12 50

Countries citing papers authored by Nathan Demars

Since Specialization
Citations

This map shows the geographic impact of Nathan Demars's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Demars with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Demars more than expected).

Fields of papers citing papers by Nathan Demars

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Demars. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Demars. The network helps show where Nathan Demars may publish in the future.

Co-authorship network of co-authors of Nathan Demars

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Demars. A scholar is included among the top collaborators of Nathan Demars based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Demars. Nathan Demars is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Morelli, Maria Pia, Marcelo V. Negrão, Matthew R. Collinson-Pautz, et al.. (2023). Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.. Journal of Clinical Oncology. 41(16_suppl). 2547–2547. 6 indexed citations
3.
Negrão, Marcelo V., Maria Pia Morelli, Amir A. Jazaeri, et al.. (2022). First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2679–TPS2679. 1 indexed citations
4.
McCord, Matthew, Rimas V. Lukas, Christina Amidei, et al.. (2021). Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient. Neuro-Oncology Advances. 3(1). vdab045–vdab045. 6 indexed citations
5.
Chiocca, E. Antonio, Rimas V. Lukas, Clark C. Chen, et al.. (2020). Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.. Journal of Clinical Oncology. 38(15_suppl). 2510–2510. 3 indexed citations
6.
Goldman, Stewart, Sabine Mueller, Susan Chi, et al.. (2020). CTIM-27. PHASE I/II STUDY OF CONTROLLED IL-12 AS IMMUNOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology. 22(Supplement_2). ii39–ii39. 1 indexed citations
7.
Lukas, Rimas V., Sylvia C. Kurz, John S. Yu, et al.. (2020). Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone.. Journal of Clinical Oncology. 38(15_suppl). 2564–2564. 1 indexed citations
8.
Chiocca, E. Antonio, Rimas V. Lukas, John S. Yu, et al.. (2020). Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas.. Journal of Clinical Oncology. 38(15_suppl). 3040–3040. 1 indexed citations
9.
Chiocca, E. Antonio, Rimas V. Lukas, Ganesh Rao, et al.. (2019). Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.. Journal of Clinical Oncology. 37(15_suppl). 2020–2020. 4 indexed citations
10.
Lebel, François, John Barrett, Heather L. McArthur, et al.. (2018). Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.. Journal of Clinical Oncology. 36(15_suppl). 3038–3038. 3 indexed citations
11.
Chiocca, E. Antonio, Rimas V. Lukas, John S. Yu, et al.. (2018). ATIM-15. A PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN ADULTS WITH RECURRENT GLIOBLASTOMA: DOSE DETERMINATION WITH UPDATED OVERALL SURVIVAL. Neuro-Oncology. 20(suppl_6). vi3–vi4. 2 indexed citations
12.
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Virginia Laspidea Breakdown of academic impact, for papers by Carmel Rice Breakdown of academic impact, for papers by Jaap A. van Doesum Breakdown of academic impact, for papers by Cody Coblentz Breakdown of academic impact, for papers by Valentina Bonuomo Breakdown of academic impact, for papers by Jérôme Paillassa Breakdown of academic impact, for papers by Nelli Frank Breakdown of academic impact, for papers by Daniel de la Nava Breakdown of academic impact, for papers by Pere Barba Breakdown of academic impact, for papers by Suki Subbiah
Rankless by CCL
2026